New gene-editing therapy may lower cholesterol permanently, study finds

A new CRISPR-based gene-editing therapy shows promise for treating severe high cholesterol by disabling the ANGPTL3 gene. Early trial results in 15 patients demonstrated significant reductions in LDL cholesterol and triglycerides, potentially offering a one-time, long-lasting solution for difficult-to-manage cases.